The World Health Organization this week issued a target product profile report for in vitro diagnostic tests to detect serious bacterial infections in newborns and babies aged 2 months and younger.

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 third quarter, which ended June 30, 2025.

Original from: QIAGEN ¡¤ Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 - Net sales +6% CER (constant exchange rates) above outlook for at least +5% C..

Personalis reported after the close of the market on Tuesday a 24 percent year-over-year drop in second quarter revenues, missing analyst expectations and prompting the company to slash its full-year sales guidance.

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025.

Original from: QuidelOrtho Second Quarter 2025 Results (all comparisons are to the prior year period) ¡¤ Total revenue was $614 million, as reported - Non-respiratory revenue was $567 ..

1.5 Gestation Category The most widely used professional and over the counter (OTC) patient self-tests for women¡¯s health are pregnancy and ovulation tests. OTC includes tests offered by pharmacies and other re..

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025.

Roche on Monday announced that its Cobas Respiratory 4-flex test for SARS-CoV-2, influenza A/B, and respiratory syncytial virus has received clearance from the US Food and Drug Administration.

Wantai Bio¡¯s Wind ESG Rating Soars to AA, Ranking in the Top 7% of Listed Companies in A-Share and Hong Kong Markets Recently, Wantai Bio achieved an upgrade to an AA rating in the presti..

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finderopens in a new tab, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations¡ªenhancing the user experience and freeing up more time for patient care.

Original from: Illumina ¡¤ Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis ¡¤ GAAP operating margin of 20.2% and non-GAAP operating margin ..

China has officially launched the second phase of its pilot program for Laboratory Developed Tests (LDTs), marking another significant step in promoting innovation and self-reliant diagnostic capabilities across its healthcare system.

Original from: Diasorin - REVENUES: € 619 MILLION, +5% COMPARED TO H1¡¯24 (+6% AT CER, +8% AT CER AND EXCLUDING COVID REVENUES), CONFIRMING THE FY¡¯25 GUIDANCE; - ADJUSTED1 EBITDA2: € 214 MILLION..

President Donald Trump has demanded ¡°binding commitments¡± from 17 pharmaceutical companies to lower drug prices, escalating his efforts to cut consumer costs and sending their share prices lower.

Siemens Healthineers AG today announces its results for the third quarter of fiscal year 2025 ended June 30, 2025.